thalidomide has been researched along with krn 7000 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, DH; Dhodapkar, MV; Hassoun, H; Jagannath, S; Klimek, V; Liu, N; Mazumder, A; Nimer, SD | 1 |
| Dhodapkar, KM; Dhodapkar, MV; Miesowicz, F; Monesmith, T; Nair, S; Neparidze, N; Richter, J; Sundaram, R; Zhang, L | 1 |
| Benson, DM | 1 |
1 trial(s) available for thalidomide and krn 7000
| Article | Year |
|---|---|
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Dendritic Cells; Drug Synergism; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Middle Aged; Monocytes; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
2 other study(ies) available for thalidomide and krn 7000
| Article | Year |
|---|---|
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
Topics: Antigen Presentation; Cells, Cultured; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Ligands; Lymphocyte Activation; Multiple Myeloma; Thalidomide | 2006 |
Can NKT cells extinguish smoldering myeloma?
Topics: Dendritic Cells; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2013 |